We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi Ending Collaboration With Ardelyx on NaP2b Program
Sanofi Ending Collaboration With Ardelyx on NaP2b Program
Sanofi will terminate its 19-month collaboration with Ardelyx, effective Sept. 30, ending an alliance that focused on developing NaP2b phosphate inhibitors for kidney disease.